Clinical Trials Funding Announced

  The AGITG welcomes the recent announcement by Minister Hunt, Federal Minister of Health, of a $33 million funding package to lift clinical trials and registries capacity and better support clinician researchers. This is a critical first step towards ensuring health and medical research is focused on maximising public benefit. … Read More

May 24, 2017

Senate Inquiry into Funding for Research

On 29 November 2016 the Senate established the Select Committee into ‘Funding for Research into Cancers with Low Survival Rates’ to inquire and report on the impact of health research funding models and the availability of funding for research into cancers with low survival rates. The committee is to inquire … Read More

May 19, 2017

AGITG at ASCO 2017

AGITG Abstracts to be presented at ASCO include ICECREAM and INTEGRATE II. They are now available online. 1. Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with … Read More

May 18, 2017

Welcoming our new CAP members!

On Thursday 11 May our Consumer Advisory Panel (CAP) met in Sydney – welcoming five new members to the Panel and farewelling two longstanding members – Dan Kent and Joe Levin. Established in 2008, the CAP comprises of GI cancer survivors, patients and carers. All CAP members volunteer their time … Read More

May 18, 2017

Deciding on a future in the field of Upper GI Cancer

Supported by an education sponsorship by Shire, 39 early career cancer clinicians – including consultants in Medical, Radiation and Surgical Oncology – gathered earlier in May to learn from the experts at the AGITG Preceptorship in Upper GI Cancer. This two day intensive learning course involves a complete review of … Read More

May 18, 2017

AGITG Trial News

The AGITG currently has eight  studies open to recruitment and ten  studies in follow up. The  table below details  the trials that  are currently  accruing patients. Recruited Target ACTICCA-1- Gallbladder carcinoma 2 50 ALT-GIST- GI Stromal Tumour 52 60 ASCOLT — Colorectal cancer 207 300 CONTROL NETs — NeuroEndocrine Tumour … Read More

May 1, 2017

AGITG Innovation Fund – Open for Applications

The AGITG Innovation Fund is made possible through generous contributions from the Spencer Gibson Foundation, the His Honour Alan Bishop Fund and with donations raised through the GI Cancer Institute’s Gutsy Challenge. AGITG members can apply for up to $200,000 to support a new AGITG pilot trial. “The AGITG Innovation … Read More

April 18, 2017

Merck partners with the AGITG

The AGITG in partnership with Merck are pleased to announce two exciting opportunities for AGITG members. “With generous untied financial support from Merck, two significant opportunities are available for our membership through the AGITG Clinical Research Fellowship in GI Cancer and the Kristian Anderson Award.  These opportunities, provided by Merck, … Read More

April 12, 2017

CHALLENGE clinical trial

CHALLENGE: Colon Health And Life Long Exercise change A phase III study of the impact of a physical activity program on disease-free survival in patients with high risk stage II or stage III colon cancer A clinical trial endorsed by the AGITG The CHALLENGE trial is now running in 7 … Read More

April 12, 2017

CAP makes submission to Senate Inquiry

On 29 November 2016 the Senate established a select committee known as the Select Committee into Funding for Research into Cancers with Low Survival Rates to inquire and report on the impact of health research funding models on the availability of funding for research into cancers with low survival rates. … Read More

April 12, 2017